Reports

Sale

Schizophrenia Market

Schizophrenia Market Size, Share, Growth, Trends, Forecast: By Type: Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia, Undifferentiated Schizophrenia; By Treatment; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Schizophrenia Market Outlook

The schizophrenia market size was valued at USD 7.78 billion in 2023, driven by the rising prevalence of schizophrenia and heightened awareness surrounding mental health disorders across the 8 major markets. The market is expected to grow at a CAGR of 5.80% during the forecast period of 2024-2032, with the values likely to rise from USD 8.23 billion in 2024 to USD 12.92 billion by 2032.

 

Schizophrenia Market Overview

Schizophrenia includes a spectrum of disorders linked to psychosis and disconnection from reality. Characterized by cognitive, behavioral, and emotional impairment, the chronic mental disorder can cause delusions, confused speech, and social withdrawal. Schizophrenia ranks among the top 10 causes of global disability and is estimated to affect nearly 1% of the population.  The increasing prevalence of schizophrenia and rising awareness of mental disorders are driving demand for effective treatment solutions, propelling the schizophrenia market growth.

 

To accommodate the growing demand for innovative therapeutics for schizophrenia treatment, several key players in the market are engaging in mergers and acquisition activities. One such event was witnessed in December 2023, with the global pharmaceutical company Bristol Myers Squibb  announcing its acquisition of Karuna Therapeutics for USD 14 billion. The pharmaceutical giant plans to drive growth through the Karuna Therapeutic’s schizophrenia drug, KarXT, currently under United States Food and Drug Administration (FDA) review. The drug offers a novel mechanism of action with potentially fewer adverse effects compared to existing antipsychotic treatments. It is expected to be marketed in September 2024, post-approval from the FDA.

 

The schizophrenia market demand is further bolstered by the rising geriatric population at risk of developing schizophrenia and other related mental disorders. The rising mental health campaigns and initiatives by the government to improve patient outcomes are also anticipated to accelerate the market growth in the forecast period.

 

Schizophrenia Market Segmentation

Market Breakup by Type

  • Paranoid Schizophrenia
  • Hebephrenic Schizophrenia
  • Catatonic Schizophrenia
  • Undifferentiated Schizophrenia

 

The schizophrenia market is categorized into different types based on the symptoms and clinical features. It includes paranoid, hebephrenic, catatonic, and undifferentiated schizophrenia. Treatment approaches usually differ depending on the type of schizophrenia and severity of symptoms.

 

Market Breakup by Treatment

  • Second Generation Antipsychotics
    • Invega (Paliperidone) 
    • Zyprexa (Olanzapine)
    • Geodon (Ziprasidone)
    • eoquel(Quetiapine) 
    • Latuda (Lurasidone)
    • Saphris (Asenapine)
    • Vraylar (Cariprazine)
    • Risperdal (Risperidone)
  • Third Generation Antipsychotics
    • Abilify (Aripiprazole)

 

Based on treatment, the schizophrenia market share is segmented into second generation antipsychotics (SGAs) and third generation antipsychotics (TGAs). Second generation antipsychotics include medications like Invega, Zyprexa, Geodon, Seroquel, Latuda, Saphris, Vraylar, and Risperdal, known to target various neurotransmitter systems to manage psychotic symptoms. Third generation antipsychotics include Abilify, which shows fewer side effects as compared to conventional antipsychotics.

 

Market Breakup by Route of Administration

  • Oral
  • Injectable
  • Spinal Tap
  • Muscle Biopsy
  • Others

 

The schizophrenia market is segmented by route of administration into oral, injectable, spinal tap, muscle biopsy, and others.

 

Market Breakup by End User

  • Hospitals & Clinics
  • Cancer Research Centers
  • Others

 

The schizophrenia market report is segmented by end users into hospitals and clinics, cancer research centers, and others. These segments provide support services for individuals affected by schizophrenia.

 

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

 

Distribution channels facilitate access to antipsychotic medications, catering to diverse patient needs suffering from schizophrenia. It includes hospital pharmacy, retail pharmacy, online pharmacy, and others.

 

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

 

The report covers 8 major markets poised to witness significant growth in upcoming years. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America is the leading player in the market. The elevated schizophrenia market size can be attributed to the rising geriatric population, presence of an advanced healthcare system, and the increased prevalence of schizophrenia in the region.

 

Schizophrenia Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Johnson & Johnson
  • Bristol Myers Squibb
  • AstraZeneca
  • Eli Lilly And Company
  • Sumitomo Dainippon Pharma
  • Pfizer Inc.
  • Vanda Pharmaceuticals
  • Allergan
  • H. Lundbeck A/S
  • Alkermes plc
  • AbbVie Inc.
  • Acadia Pharmaceuticals

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type 
  • Treatment 
  • Route of Administration
  • End User
  • Distribution Channel
  • Region
Breakup by Type 
  • Paranoid Schizophrenia 
  • Hebephrenic Schizophrenia 
  • Catatonic Schizophrenia 
  • Undifferentiated Schizophrenia  
Breakup by Treatment 
  • Second Generation Antipsychotics
  • Third Generation Antipsychotics
Breakup by Route of Administration
  • Injectable 
  • Spinal Tap 
  • Muscle Biopsy 
  • Others
Breakup by End User
  • Hospitals & Clinics 
  • Cancer Research Centers 
  • Others 
Breakup by Distribution Channel
  • Hospital Pharmacy 
  • Retail Pharmacy 
  • Online Pharmacy 
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Johnson & Johnson 
  • Bristol Myers Squibb 
  • AstraZeneca 
  • Eli Lilly And Company 
  • Sumitomo Dainippon Pharma 
  • Pfizer Inc. 
  • Vanda Pharmaceuticals 
  • Allergan  
  • H. Lundbeck A/S 
  • Alkermes plc
  • AbbVie Inc.  
  • Acadia Pharmaceuticals 

 

Key Queries Solved in the Schizophrenia Market Report

  • How will the market landscape evolve in the coming years? 
  • What are the major market trends influencing the market? 
  • What are the major drivers, opportunities, and restraints in the market? 
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which country is poised to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • What is the prevalence of schizophrenia? How is it distributed across different demographics?
  • What factors impact the schizophrenia market demand?
  • What are the different types of schizophrenia treatments available in the market?
  • What are the latest advancements in schizophrenia drug research and development?
  • What are the major drug approvals to manage schizophrenia during the historical period?
  • How is the market segmented by end users, distribution channel, and geography?
  • Which major companies are expected to impact the market significantly?
  • What investments and funding are driving research and development in the schizophrenia market?
  • What are the key strategies adopted by leading pharmaceutical companies to gain market share?
  • How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics of the schizophrenia market?

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Schizophrenia Market Overview – 8 Major Markets 
    3.1    Schizophrenia Market Historical Value (2017-2023) 
    3.2    Schizophrenia Market Forecast Value (2024-2032) 
4    Schizophrenia Overview 
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Schizophrenia Epidemiology Scenario and Forecast – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
    6.2    United States Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
    6.3    EU-4 and United Kingdom Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
        6.3.1    Germany Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
        6.3.2    France Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
        6.3.3    Italy Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
        6.3.4    Spain Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
        6.3.5    United Kingdom Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
    6.4    Japan Schizophrenia Epidemiology Scenario and Forecast (2017-2032) 
    6.5    India Schizophrenia Epidemiology Scenario and Forecast (2017-2032)
7    Schizophrenia Market Landscape – 8 Major Markets 
    7.1    Schizophrenia: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Schizophrenia: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Treatment 
8    Schizophrenia Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Schizophrenia Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Schizophrenia Market Segmentation (2017-2032) - 8 Major Markets 
    11.1    Schizophrenia Market (2017-2032) by Type 
        11.1.1    Market Overview
        11.1.2    Paranoid Schizophrenia 
        11.1.3    Hebephrenic Schizophrenia 
        11.1.4    Catatonic Schizophrenia 
        11.1.5    Undifferentiated Schizophrenia  
    11.2    Schizophrenia Market (2017-2032) by Treatment 
        11.2.1    Market Overview
        11.2.2    Second Generation Antipsychotics
            11.2.2.1    Invega (Paliperidone)  
            11.2.2.2    Zyprexa (Olanzapine) 
            11.2.2.3    Geodon (Ziprasidone) 
            11.2.2.4    Seoquel(Quetiapine) 
            11.2.2.5    Latuda (Lurasidone) 
            11.2.2.6    Saphris (Asenapine) 
            11.2.2.7    Vraylar (Cariprazine) 
            11.2.2.8    Risperdal (Risperidone)
        11.2.3    Third Generation Antipsychotics
            11.2.3.1    Abilify (Aripiprazole) 
    11.3    Schizophrenia Market (2017-2032) by Route of Administration
        11.3.1    Oral
        11.3.2    Injectable 
        11.3.3    Spinal Tap 
        11.3.4    Muscle Biopsy 
        11.3.5    Others
    11.4    Schizophrenia Market (2017-2032) by End User
        11.4.1    Market Overview
        11.4.2    Hospitals & Clinics 
        11.4.3    Cancer Research Centers 
        11.4.4    Others 
    11.5    Schizophrenia Market (2017-2032) by Distribution Channel
        11.5.1    Market Overview
        11.5.2    Hospital Pharmacy 
        11.5.3    Retail Pharmacy 
        11.5.4    Online Pharmacy 
        11.5.5    Others
    11.6    Schizophrenia Market (2017-2032) by Region
        11.6.1    Market Overview
        11.6.2    United States
        11.6.3    EU-4 and the United Kingdom
            11.6.3.1    Germany
            11.6.3.2    France
            11.6.3.3    Italy
            11.6.3.4    Spain
            11.6.3.5    United Kingdom
        11.6.4    Japan
        11.6.5    India 
12    United States Schizophrenia Market (2017-2032)
    12.1    United States Schizophrenia Market Historical Value (2017-2023) 
    12.2    United States Schizophrenia Market Forecast Value (2024-2032)
    12.3    United States Schizophrenia Market (2017-2032) by Type
        12.3.1    Market Overview
        12.3.2    Paranoid Schizophrenia 
        12.3.3    Hebephrenic Schizophrenia 
        12.3.4    Catatonic Schizophrenia 
        12.3.5    Undifferentiated Schizophrenia  
    12.4    United States Schizophrenia Market (2017-2032) by Route of Administration 
        12.4.1    Market Overview
        12.4.2    Oral
        12.4.3    Injectable 
        12.4.4    Spinal Tap 
        12.4.5    Muscle Biopsy 
        12.4.6    Others
13    EU-4 and United Kingdom Schizophrenia Market (2017-2032)
    13.1    EU-4 and United Kingdom Schizophrenia Market Historical Value (2017-2023) 
    13.2    EU-4 and United Kingdom Schizophrenia Market Forecast Value (2024-2032)
    13.3    EU-4 and United Kingdom Schizophrenia Market Overview
    13.4    EU-4 and United Kingdom Schizophrenia Market (2017-2032) by Type
        13.4.1    Market Overview
        13.4.2    Paranoid Schizophrenia 
        13.4.3    Hebephrenic Schizophrenia 
        13.4.4    Catatonic Schizophrenia 
        13.4.5    Undifferentiated Schizophrenia
    13.5    EU-4 and United Kingdom Schizophrenia Market (2017-2032) by Route of Administration 
        13.5.1    Market Overview
        13.5.2    Oral
        13.5.3    Injectable 
        13.5.4    Spinal Tap 
        13.5.5    Muscle Biopsy 
        13.5.6    Others
14    Japan Schizophrenia Market
    14.1    Japan Schizophrenia Market Historical Value (2017-2023) 
    14.2    Japan Schizophrenia Market Forecast Value (2024-2032)
    14.3    Japan Schizophrenia Market (2017-2032) by Type
        14.3.1    Market Overview
        14.3.2    Paranoid Schizophrenia 
        14.3.3    Hebephrenic Schizophrenia 
        14.3.4    Catatonic Schizophrenia 
        14.3.5    Undifferentiated Schizophrenia
    14.4    Japan Schizophrenia Market (2017-2032) by Route of Administration 
        14.4.1    Market Overview
        14.4.2    Oral
        14.4.3    Injectable 
        14.4.4    Spinal Tap 
        14.4.5    Muscle Biopsy 
        14.4.6    Others
15    India Schizophrenia Market
    15.1    India Schizophrenia Market (2017-2032) Historical Value (2017-2023) 
    15.2    India Schizophrenia Market (2017-2032) Forecast Value (2024-2032)
    15.3    India Schizophrenia Market (2017-2032) by Type
        15.3.1    Market Overview
        15.3.2    Paranoid Schizophrenia 
        15.3.3    Hebephrenic Schizophrenia 
        15.3.4    Catatonic Schizophrenia 
        15.3.5    Undifferentiated Schizophrenia
    15.4    India Schizophrenia Market (2017-2032) by Route of Administration 
        15.4.1    Market Overview
        15.4.2    Oral
        15.4.3    Injectable 
        15.4.4    Spinal Tap 
        15.4.5    Muscle Biopsy 
        15.4.6    Others
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    Japan PMDA
        16.1.4    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication Year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants Analysis
    18.1    Analysis by Year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier Landscape
    22.1    Johnson & Johnson 
        22.1.1    Financial Analysis 
        22.1.2    Product Portfolio 
        22.1.3    Demographic Reach and Achievements 
        22.1.4    Mergers and Acquisitions 
        22.1.5    Certifications 
    22.2    Bristol Myers Squibb 
        22.2.1    Financial Analysis 
        22.2.2    Product Portfolio 
        22.2.3    Demographic Reach and Achievements 
        22.2.4    Mergers and Acquisitions 
        22.2.5    Certifications 
    22.3    AstraZeneca 
        22.3.1    Financial Analysis 
        22.3.2    Product Portfolio 
        22.3.3    Demographic Reach and Achievements 
        22.3.4    Mergers and Acquisitions 
        22.3.5    Certifications 
    22.4    Eli Lilly And Company 
        22.4.1    Financial Analysis 
        22.4.2    Product Portfolio 
        22.4.3    Demographic Reach and Achievements 
        22.4.4    Mergers and Acquisitions 
        22.4.5    Certifications 
    22.5    Sumitomo Dainippon Pharma 
        22.5.1    Financial Analysis 
        22.5.2    Product Portfolio 
        22.5.3    Demographic Reach and Achievements 
        22.5.4    Mergers and Acquisitions 
        22.5.5    Certifications 
    22.6    Pfizer Inc. 
        22.6.1    Financial Analysis 
        22.6.2    Product Portfolio 
        22.6.3    Demographic Reach and Achievements 
        22.6.4    Mergers and Acquisitions 
        22.6.5    Certifications 
    22.7    Vanda Pharmaceuticals 
        22.7.1    Financial Analysis 
        22.7.2    Product Portfolio 
        22.7.3    Demographic Reach and Achievements 
        22.7.4    Mergers and Acquisitions 
        22.7.5    Certifications 
    22.8    Allergan   
        22.8.1    Financial Analysis 
        22.8.2    Product Portfolio 
        22.8.3    Demographic Reach and Achievements 
        22.8.4    Mergers and Acquisitions 
        22.8.5    Certifications 
    22.9    H. Lundbeck A/S   
        22.9.1    Financial Analysis 
        22.9.2    Product Portfolio 
        22.9.3    Demographic Reach and Achievements 
        22.9.4    Mergers and Acquisitions 
        22.9.5    Certifications 
    22.10    Alkermes plc
        22.10.1    Financial Analysis 
        22.10.2    Product Portfolio 
        22.10.3    Demographic Reach and Achievements 
        22.10.4    Mergers and Acquisitions 
        22.10.5    Certifications 
    22.11    AbbVie Inc.  
        22.11.1    Financial Analysis 
        22.11.2    Product Portfolio 
        22.11.3    Demographic Reach and Achievements 
        22.11.4    Mergers and Acquisitions 
        22.11.5    Certifications 
    22.12    Acadia Pharmaceuticals  
        22.12.1    Financial Analysis 
        22.12.2    Product Portfolio 
        22.12.3    Demographic Reach and Achievements 
        22.12.4    Mergers and Acquisitions 
        22.12.5    Certifications
List not exhaustive
23 Schizophrenia Treatment Drugs - Distribution Model (Additional Insight)  
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)
    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

    
 *Additional insights provided are customisable as per client requirements.
 
 
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

What was the schizophrenia market value in 2023?  

The market attained a value of about USD 7.78 billion in 2023 driven by the rising prevalence of schizophrenia and heightened awareness surrounding mental health disorders across the 8 major markets.

What is the schizophrenia market forecast outlook for 2024-2032?  

The market is anticipated to grow at a CAGR of 5.80% during the forecast period of 2024-2032, likely to reach a market value of USD 12.92 billion by 2032.

What are the major factors aiding the schizophrenia market demand?  

The market demand is bolstered by the rising geriatric population at risk of developing schizophrenia and other related mental disorders.

What are the major schizophrenia market trends? 

One of the significant trends is the rising acquisition and merger initiatives by the key players in the market. In December 2023, Bristol Myers Squibb announced the acquisition of Karuna Therapeutics for USD 14 billion. The acquisition aimed at driving growth through Karuna Therapeutic’s schizophrenia drug, KarXT, currently under United States Food and Drug Administration (FDA) review.

What is the market segmentation based on the type?

The market is segmented into paranoid, hebephrenic, catatonic, and undifferentiated types of schizophrenia.

What are treatments available in the market?

Based on treatment, the market is segmented into second generation antipsychotics (SGAs) and third generation antipsychotics (TGAs). Second generation antipsychotics include medications like Invega, Zyprexa, Geodon, Seroquel, Latuda, Saphris, Vraylar, and Risperdal, whereas third generation antipsychotics include Abilify.

What is the market based on the route of administration?

The market is segmented by route of administration into oral, injectable, spinal tap, muscle biopsy, and others.

What are the major end users of the market?

The market is segmented by end users into hospitals and clinics, cancer research centers, and others.
 

What are the distribution channels of the schizophrenia market?

Distribution channels include hospital pharmacy, retail pharmacy, online pharmacy, and others.

What are the major regional markets for schizophrenia, according to the EMR report? 

The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. 

Who are the key players involved in the schizophrenia market? 

Key players involved in the market are Johnson & Johnson, Bristol Myers Squibb, AstraZeneca, Eli Lilly and Company, Sumitomo Dainippon Pharma, Pfizer Inc., Vanda Pharmaceuticals, Allergan, H. Lundbeck A/S, Alkermes plc, AbbVie Inc., and Acadia Pharmaceuticals.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER